These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34694927)

  • 1. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate.
    Choi EJ; Xu P; Barham D; El-Khatib FM; Yafi FA; Kavoussi PK
    J Urol; 2022 Mar; 207(3):677-683. PubMed ID: 34694927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-market safety and efficacy profile of subcutaneous testosterone enanthate-autoinjector: a cohort analysis.
    Choi EJ; Xu P; El-Khatib FM; Kavoussi PK; Yafi FA
    Int J Impot Res; 2022 Aug; 34(5):467-470. PubMed ID: 34007063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
    Gittelman M; Jaffe JS; Kaminetsky JC
    J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
    Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
    J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
    Borst SE; Yarrow JF
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
    Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
    Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The five-year effects of testosterone replacement therapy on lipid profile and glucose tolerance among hypogonadal men in Japan: a case control study.
    Kato Y; Shigehara K; Nakashima K; Iijima M; Kawagushi S; Nohara T; Izumi K; Kadono Y; Konaka H; Namiki M; Mizokami A
    Aging Male; 2020 Mar; 23(1):23-28. PubMed ID: 30651019
    [No Abstract]   [Full Text] [Related]  

  • 14. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
    Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
    J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.